ID: ALA2417783

Max Phase: Preclinical

Molecular Formula: C18H23N3O3S

Molecular Weight: 361.47

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1onc(-c2ccccc2)c1C(=O)NCCCCCNC(=O)CS

Standard InChI:  InChI=1S/C18H23N3O3S/c1-13-16(17(21-24-13)14-8-4-2-5-9-14)18(23)20-11-7-3-6-10-19-15(22)12-25/h2,4-5,8-9,25H,3,6-7,10-12H2,1H3,(H,19,22)(H,20,23)

Standard InChI Key:  WWLIISZAGFGMDE-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 361.47

Molecular Weight (Monoisotopic): 361.1460

AlogP: 2.60

#Rotatable Bonds: 9

Polar Surface Area: 84.23

Molecular Species: NEUTRAL

HBA: 5

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.45

CX Basic pKa:

CX LogP: 1.92

CX LogD: 1.91

Aromatic Rings: 2

Heavy Atoms: 25

QED Weighted: 0.47

Np Likeness Score: -1.15

References

1. Kalin JH, Bergman JA..  (2013)  Development and therapeutic implications of selective histone deacetylase 6 inhibitors.,  56  (16): [PMID:23627282] [10.1021/jm4001659]

2. Wang XX,Wan RZ,Liu ZP.  (2018)  Recent advances in the discovery of potent and selective HDAC6 inhibitors.,  143  [PMID:29133060] [10.1016/j.ejmech.2017.10.040]

3. Tavares MT, Kozikowski AP, Shen S..  (2021)  Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors.,  209  [PMID:33035922] [10.1016/j.ejmech.2020.112887]

Source

Source(1):

• Scientific Literature